Colorectal disorders:

Indications for: CANASA

Mild to moderately active ulcerative proctitis.

Adult Dosage:

Retain supp in rectum for at least 1–3hrs. 1g once daily at bedtime. Treat for 3–6 weeks.

Children Dosage:

Not established.

CANASA Warnings/Precautions:

Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. May stain clothes. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

CANASA Classification:

Aminosalicylate.

CANASA Interactions:

Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.

Adverse Reactions:

Dizziness, rectal pain, fever, rash, acne, colitis, headache, flatulence, abdominal pain, diarrhea, nausea; renal impairment, mesalamine-induced acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).

Metabolism:

Hepatic.

Drug Elimination:

Renal.

Generic Drug Availability:

YES

How Supplied:

Supps—30, 42